简介：目的探讨表而麻醉下小切口囊袋内圈垫式切核白内障囊外摘除术的手术疗效。方法表面麻醉下对116眼（96例）白内障行小切口囊袋内圈垫式切核白内障摘除术,记录术中患者眼疼痛情况及手术时间,术后角膜水肿情况、最佳矫正视力及手术并发症。结果116眼手术均在表面麻醉下完成,术中疼痛分级情况：0级96眼,1级14眼,2级6眼,3级0眼。手术平均时间为13.6±3.5min。术后第1天最佳矫正视力情况：0.2-0.4者16眼,0.5-0.8者82眼,≥1.0者18眼。术后第一天角膜水肿情况：角膜内皮纹样水肿28眼,均于术后3天左右消退;局部斑片样混浊3眼,术后1周内消退。结论表面麻醉下小切口囊袋内圈垫式切核白内障摘除术具有术中操作简便,手术时间短,前房操作空间大,并发症少等优点。

简介：目的观察微小切口非超声乳化白内障摘除联合折叠式人工晶状体植入术手术效果.方法抽选107例（107眼）行微小切口非超声乳化白内障摘除联合折叠式人工晶状体植入术,112例（112眼）行小切口非超声乳化白内障摘除联合硬片人工晶状体植入术,比较术后1周视力.结果术后1周视力大于0.3者分别为88.78％及66.96％.结论微小切口非超声乳化白内障摘除联合折叠式人工晶状体植入术术后1周视力优于小切口非超声乳化白内障摘除联合硬片人工晶状体植入术,术后近期（1周）效果与超声乳化近期（1周）效果相近,在缺少设备、缺少投入的基层医院值得推广使用.

简介：目的评价小切口超声乳化及大直径折叠式人工晶体植入对于治疗高度近视性白内障的安全性和疗效.方法表面麻醉下对40例68只眼高度近视白内障患者施行透明角膜3.2mm切口超声乳化吸除,植人大直径后房型折叠式人工晶体.观察术中的安全性及术后疗效.结果术中无一例发生后囊膜破裂、前房出血以及爆发性脉络膜上腔出血.术后1天裸眼或矫正视力≥0.5者,占54.41%;术后1周为70.59%;1个月为82.35%;视力≥1.0者,术后1天为8.82%、术后1周为25%、1个月为41.18%.结论小切口超声乳化及大直径折叠式人工晶体植入治疗高度近视白内障,具有视力恢复快、无严重并发症等特点,但是对手术技巧要求较高.术后视力提高与高度近视眼底病变有关.

简介：AIM:Toadaptthelowvision-relatedqualityoflife(LVQOL)instrumentintoTurkishlanguageandtoassessitsvalidityandreliability.METHODS:Thestudywasconductedin387patientsattendingtheCentreofLowVisionRehabilitation,FacultyofMedicine,AnkaraUniversity.Forstatisticalanalyses,theSpearman’scorrelationcoefficient,Cronbach’salphacoefficientandConfirmatoryFactorAnalysis(CFA)wereused.RESULTS:AccordingtoresultsofCFA,theiteminthe'Adjustment'subscalebecauseofhavingthefactorloadingbelow0.40,wasexcludedfromthequestionnaire.ThereliabilityofthequestionnairewasassessedaccordingtoCronbach’salphacoefficients.Thereliabilityofthe'DistanceVision,Mobility,andLighting'subscalewas?琢=0.863;ofthe'Adjustment'subscalewas?琢=0.694;'ReadingandFineWork'was?琢=0.791,and'ActivitiesofDailyLiving'was?琢=0.770.Sotheseresultsindicatethatthequestionnaireisreliabletomeasurethevisionrelatedqualityoflifeoflow-visionpatients.Thecorrelationsbetweenthesubscaleswerealsoanalyzed,andthecorrelationbetween'Adjustment'and'ReadingandFineWork'wasfoundtobethelowest(rs=0.336,P<0.001),whereasthestrongestcorrelationwasfoundbetweenthe'ReadingandFineWork',and'ActivitiesofDailyLiving'.Additionally,the'Adjustment'dimensionshowedthestrongestcorrelationwithonly'DistanceVision,Mobility,andLighting'dimension.CONCLUSION:Afterremovingthelastitemintheseconddimension,theTurkishadaptationofalldimensionsoftheLVQOLhasbeenshowntobereliable,validandsuitableforuseinpatientswithlowvisioninTurkey.

简介：目的：系统评价拉坦前列素（Latanoprost）滴眼液与噻吗心安（Timolol）滴眼液降眼压的有效性和安全性。方法：计算机检索PubMed，Medline，CNKI及中国生物医学文献数据库收录的，并辅以手工检索、因特网搜索的有关拉坦前列素与噻吗心安治疗原发性开角型青光眼和高眼压症的随机对照试验（RCT）。按照纳入和排除标准限定研究对象，通过Jadad评分量表进行文献质量评估后，针对眼压下降比例、药物不良反应2项内容，使用Cochrane协作网提供的RevMan5．0软件进行Meta分析。结果：共纳入9项RCT，合计555例患者。Meta分析结果显示：（1）拉坦前列素滴眼液与噻吗心安滴眼液降眼压效果，在2，6，12wk时差异均有统计学意义（P＜0．01），加权平均差（WMD）分别为：在2wk[WMD＝-0．76，95％CI（-1．32，-0．20）]，在6wk[WMD＝-1．15，95％CI（-1．68，0．63）]和12wk[WMD＝-1．01，95％CI（-1．42，-0．61）]。（2）随访结束时，结膜充血、异物感为拉坦前列素的两种较为常见的不良反应，但其发生率拉坦前列素组与噻吗心安组比较，结膜充血的发生率[OR＝2．25，95％CI（0．99，5．08）]，异物感的发生率[OR＝2．48，95％CI（1．02，6．03）]，显示二者差异均无统计学意义。结论：治疗原发性开角型青光眼和高眼压症，拉坦前列素降眼压效果在用药12wk内较噻吗心安好；两者在12wk内引起结膜充血、异物感、虹膜色素加深、视野损害等的不良反应方面，差异不明显。由于纳入研究的样本量偏小，且方法学质量中等，致使本系统评价结果论证强度不高，因此还需要开展更多的高质量的临床随机对照研究，以便更客观、准确、全面地评价其疗效和安全性。

简介：AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.